Literature DB >> 31008801

Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.

Jane A O'Halloran1, Sarah A Cooley2, Jeremy F Strain2, Anna Boerwinkle2, Robert Paul3, Rachel M Presti1, Beau M Ances2,4.   

Abstract

OBJECTIVES: Neuropsychiatric symptoms have been reported in people living with HIV (PLWH) on integrase strand transfer inhibitors (INSTIs) in postmarketing analysis. Limited data exist regarding brain integrity (function and structure) in PLWH prescribed INSTIs compared with other HIV treatment regimens.
DESIGN: A cross-sectional analysis of PLWH on combined antiretroviral therapy aged more than 18 years at a single institution.
METHODS: Neuropsychological tests were administered to calculate domain deficit scores in learning/memory, executive function and motor/psychomotor domains. Cortical and subcortical volumes from MRI were obtained using the FreeSurfer software suite (v5.3).
RESULTS: Of 202 participants, median age 55 (48, 60) years old, 49% were on INSTI-based combined antiretroviral therapy. PLWH on INSTIs were similar to individuals on non-INSTIs in terms of age, sex, race, education years, smoking history, depression scores, psychiatric medication use, presence of hepatitis C infection, history of substance use, HIV infection duration and recent or nadir CD4 T-cell count. Participants in the INSTI group performed worse than non-INSTI users in the verbal learning and memory domain [1.5 (interquartile range 0, 2.5) versus 1 (0, 2); P = 0.016]. The INSTI and non-INSTI groups were similar for other cognitive domains. Frontal, brain stem and cerebellar volumes were reduced in INSTI compared with non-INSTI users (all P = <0.05).
CONCLUSION: We demonstrated modest differences in learning/memory performance and smaller brain volumes in PLWH on INSTI-based regimens compared with non-INSTI users. Prospective studies are needed to define mechanisms and the clinical significance of reduced brain integrity in PLWH on INSTIs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31008801      PMCID: PMC8194092          DOI: 10.1097/QAD.0000000000002236

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  42 in total

1.  Norms for letter and category fluency: demographic corrections for age, education, and ethnicity.

Authors:  J A Gladsjo; C C Schuman; J D Evans; G M Peavy; S W Miller; R K Heaton
Journal:  Assessment       Date:  1999-06

Review 2.  Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.

Authors:  Jacob Gray; Benjamin Young
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

3.  The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

Authors:  Jaime H Vera; Akil Jackson; Laura Dickinson; Laura Else; Tristan Barber; Borja Mora-Peris; David Back; Marta Boffito; Alan Winston
Journal:  HIV Clin Trials       Date:  2015-01-14

4.  Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals.

Authors:  Ryan Sanford; Lesley K Fellows; Beau M Ances; D Louis Collins
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

5.  Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity.

Authors:  A L Piatt; J A Fields; A M Paolo; A I Tröster
Journal:  Neuropsychologia       Date:  1999-12       Impact factor: 3.139

6.  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

Authors:  A T Beck; R A Steer; R Ball; W Ranieri
Journal:  J Pers Assess       Date:  1996-12

7.  Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

Authors:  N Ciccarelli; M Fabbiani; S Di Giambenedetto; I Fanti; E Baldonero; L Bracciale; E Tamburrini; R Cauda; A De Luca; M C Silveri
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

8.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Authors:  Sharon L Walmsley; Antonio Antela; Nathan Clumeck; Dan Duiculescu; Andrea Eberhard; Felix Gutiérrez; Laurent Hocqueloux; Franco Maggiolo; Uriel Sandkovsky; Catherine Granier; Keith Pappa; Brian Wynne; Sherene Min; Garrett Nichols
Journal:  N Engl J Med       Date:  2013-11-07       Impact factor: 91.245

9.  Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Authors:  Qing Ma; Florin Vaida; Jenna Wong; Chelsea A Sanders; Yu-ting Kao; David Croteau; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; Susan Morgello; David M Simpson; Robert K Heaton; Igor Grant; Scott L Letendre
Journal:  J Neurovirol       Date:  2015-09-25       Impact factor: 2.643

10.  High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.

Authors:  Andrea Calcagno; Jessica Cusato; Marco Simiele; Ilaria Motta; Sabrina Audagnotto; Margherita Bracchi; Antonio D'Avolio; Giovanni Di Perri; Stefano Bonora
Journal:  J Antimicrob Chemother       Date:  2013-08-23       Impact factor: 5.790

View more
  12 in total

Review 1.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

2.  Cognitive Phenotypes of HIV Defined Using a Novel Data-driven Approach.

Authors:  Robert H Paul; Kyu Cho; Andrew Belden; Adam W Carrico; Eileen Martin; Jacob Bolzenius; Patrick Luckett; Sarah A Cooley; Julie Mannarino; Jodi M Gilman; Mariah Miano; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-04       Impact factor: 4.147

3.  Longitudinal Effects of Combination Antiretroviral Therapy on Cognition and Neuroimaging Biomarkers in Treatment-Naive People With HIV.

Authors:  Miriam T Weber; Alan Finkelstein; Md Nasir Uddin; Elizabeth Asiago Reddy; Roberto C Arduino; Lu Wang; Madalina E Tivarus; Jianhui Zhong; Xing Qiu; Giovanni Schifitto
Journal:  Neurology       Date:  2022-06-22       Impact factor: 11.800

4.  Accelerated Brain Aging and Cerebral Blood Flow Reduction in Persons With Human Immunodeficiency Virus.

Authors:  Kalen J Petersen; Nicholas Metcalf; Sarah Cooley; Dimitre Tomov; Florin Vaida; Robert Paul; Beau M Ances
Journal:  Clin Infect Dis       Date:  2021-11-16       Impact factor: 9.079

5.  Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.

Authors:  Anna Prats; Ignacio Martínez-Zalacaín; Beatriz Mothe; Eugènia Negredo; Núria Pérez-Álvarez; Maite Garolera; Sira Domènech-Puigcerver; Pep Coll; Michael Meulbroek; Anna Chamorro; Carmina R Fumaz; Maria J Ferrer; Bonaventura Clotet; Carles Soriano-Mas; Jose A Muñoz-Moreno
Journal:  Sci Rep       Date:  2021-05-28       Impact factor: 4.379

6.  Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.

Authors:  Jane A O'Halloran; Kunbo Wang; Amanda B Spence; Dionna W Williams; Raha Dastgheyb; Kathryn C Fitzgerald; Asante R Kamkwalala; Pauline M Maki; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Cecile D Lahiri; Anandi N Sheth; Yanxun Xu; Leah H Rubin
Journal:  J Acquir Immune Defic Syndr       Date:  2021-04-15       Impact factor: 3.771

7.  Effects of Framingham 10-Year Cardiovascular Risk Score and Viral Load on Brain Integrity in Persons With HIV.

Authors:  Michelle Glans; Sarah A Cooley; Florin Vaida; Anna Boerwinkle; Dimitre Tomov; Kalen J Petersen; Alexander Rosenow; Robert H Paul; Beau M Ances
Journal:  J Acquir Immune Defic Syndr       Date:  2022-05-01       Impact factor: 3.771

8.  Altered Gray Matter Volume and Functional Connectivity in Human Immunodeficiency Virus-Infected Adults.

Authors:  Dan Liu; Cui Zhao; Wei Wang; Yuanyuan Wang; Ruili Li; Jun Sun; Jiaojiao Liu; Mingming Liu; Xu Zhang; Ying Liang; Hongjun Li
Journal:  Front Neurosci       Date:  2020-12-03       Impact factor: 4.677

9.  Patterns and Predictors of Cognitive Function Among Virally Suppressed Women With HIV.

Authors:  Raha M Dastgheyb; Alison S Buchholz; Kathryn C Fitzgerald; Yanxun Xu; Dionna W Williams; Gayle Springer; Kathryn Anastos; Deborah R Gustafson; Amanda B Spence; Adaora A Adimora; Drenna Waldrop; David E Vance; Joel Milam; Hector Bolivar; Kathleen M Weber; Norman J Haughey; Pauline M Maki; Leah H Rubin
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

10.  Comparison of [11C]-PBR28 Binding Between Persons Living With HIV and HIV-Uninfected Individuals.

Authors:  Anna H Boerwinkle; Jeremy F Strain; Tricia Burdo; John Doyle; Jon Christensen; Yi Su; Julie K Wisch; Sarah A Cooley; Florin Vaida; Mandy D Smith; Hussain Jafri; Robert H Paul; Tammie L S Benzinger; Beau M Ances
Journal:  J Acquir Immune Defic Syndr       Date:  2020-10-01       Impact factor: 3.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.